Atherosclerosis in rheumatoid arthritis versus diabetes: A comparative study

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 10, 2009, Pages 1702-1708

  Stamatelopoulos, Kimon S ^a,e   Kitas, George D ^b,c   Papamichael, Christos M ^a   Chryssohoou, Elda ^a   Kyrkou, Katerina ^a   Georgiopoulos, George ^a   Protogerou, Athanassios ^a   Panoulas, Vasileios F ^b,c   Sandoo, Aamer ^b,c   Tentolouris, Nikolaos ^d   Mavrikakis, Myron ^a   Sfikakis, Petros P ^d  

^a Alexandras Hospital   (Greece)

^b DUDLEY GROUP OF HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e Alexandra Hospital   (United States)

Author keywords

Diabetes mellitus; Inflammation; Preclinical atherosclerosis; Rheumatoid arthritis

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; C REACTIVE PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CAROTID ARTERY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEX DIFFERENCE; VASCULAR ENDOTHELIUM; VASODILATATION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; PATHOLOGY; PATHOPHYSIOLOGY; PREVALENCE; RISK FACTOR; STATISTICAL MODEL;

ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; LOGISTIC MODELS; PREVALENCE; RISK FACTORS;

EID: 70349582153     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.190108     Document Type: Article

References (40)

1. Kitas GD, Erb N. Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford). 2003;42:607-613.
2. Panoulas VF, Metsios GS, Pace AV, John H, Treharne GJ, Banks MJ, Kitas GD. Hypertension in rheumatoid arthritis. Rheumatology (Oxford). 2008;47:1286-1298.
3. Quyyumi AA. Inflamed joints and stiff arteries: is rheumatoid arthritis a cardiovascular risk factor? Circulation. 2006;114:1137-1139.
4. Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, Douglas KM, Nevill AM, Jamurtas AZ, Kita M, Koutedakis Y, Kitas GD. Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis. 2009;68:242-245.
5. Dessein PH, Joffe BI, Stanwix AE. Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. J Rheumatol. 2003;30:1403-1405.
6. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107:1303-1307.
7. Del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44: 2737-2745.
8. Naveed Sattar MD, David W, McCarey MD, Hilary Capell MD, Iain B. McInnes MD. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108: 2957-2963.
9. Veldhuijzen van Zanten JJ, Kitas GD. Inflammation, carotid intima-media thickness and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther. 2008;10:102.
10. Cohn JN, Quyyumi AA, Hollenberg NK, Jamerson KA Surrogate markers for cardiovascular disease: functional markers. Circulation. 2004;109:IV31-IV46.
11. Mancini GB, Dahlöf B, Díez J. Surrogate markers for cardiovascular disease: structural markers. Circulation. 2004;109:IV22-IV30.
12. Gonzalez-Juanatey C, Llorca J, Testa A, Revuelta J, Garcia-Porrua C, Gonzalez-Gay MA. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore). 2003;82:407-413.
13. Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, Sammaritano L, Devereux RB, Schwartz JE, Levine DM, Salmon JE. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med. 2006;144:249-256.
14. Arosio E, De Marchi S, Anna Rigoni, Prior M, Delva P, Lechi A. Forearm haemodynamics, arterial stiffness and microcirculatory reactivity in rheumatoid arthritis. J Hypertens. 2007;25:1273-1278.
15. Komai N, Morita Y, Sakuta T, Kuwabara A, Kashihara N. Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol. 2007;17:385-390.
16. Stamatelopoulos KS, Lekakis JP, Vamvakou G, Katsichti P, Protogerou A, Revela I, Karatzi K, Alevizaki M, Zakopoulos N, Papamichael CM. The relative impact of different measures of adiposity on markers of early atherosclerosis. Int J Cardiol. 2007;119:139-146.
17. Ter Avest E, Stalenhoef A, De Graaf J. What is the role of non-invasive measurements of atherosclerosis in individual cardiovascular risk prediction? Clinical Science. 2007;112:507-516.
18. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332:73-78.
19. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229.
20. De Jager J, Dekker JM, Kooy A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA. Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study. Arterioscler Thromb Vasc Biol. 2006;26:1086-1109.
21. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Cardiovasc Prev Rehab. 2007;14: S1-S113.
22. Van Halm VP, Peters MJ, Voskuyl AE, Boers M, Lems WF, Visser M, Stehouwer CD, Spijkerman AM, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Smulders YM, Dijkmans BA, Nurmohamed MT. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease, a cross sectional study. The CARRE Investigation. Ann Rheum Dis. In press.
23. Bamias G, Siakavellas SI, Stamatelopoulos KS, Chryssochoou E, Papamichael C, Sfikakis PP. Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. Clin Immunol. 2008;129:249-255.
24. Nichols WW, O'Rourke MF. Properties of the arterial wall. In: McDonalds' Blood Flow in Arteries. Theoretical, Experimental, and Clinical Principles. V Edition. New York: Oxford University Press Inc; 2005: 80-82.
25. Khoury Z, Schwartz R, Gottlieb S, Chenzbraun A, Stern S, Keren A. Relation of coronary artery disease to atherosclerotic disease in the aorta, carotid and femoral arteries evaluated by ultrasound. Am J Cardiol. 1997;80:1429-1433.
26. Manheim carotid intima-media thickness consensus (2004-2006). Cerebrovascular Dis. 2007;23:75-80.
27. Honda O, Sugiyama S, Kugiyama K, Fukushima H, Nakamura S, Koide S, Kojima S, Hirai N, Kawano H, Soejima H, Sakamoto T, Yoshimura M, Ogawa H. Echolucent carotid plaques predict future coronary events in patients with coronary artery disease. J Am Coll Cardiol. 2004;43: 1177-1184.
28. Grønholdt ML, Nordestgaard BG, Schroeder TV, Vorstrup S, Sillesen H. Ultrasonic echolucent carotid plaques predict future strokes. Circulation. 2001;104:68-73.
29. Zureik M, Ducimetière P, Touboul P, Courbon D, Bonithon-Kopp C, Berr C, Magne C. Common carotid intima-media thickness predicts occurrence of carotid atherosclerotic plaques: longitudinal results From the Aging Vascular Study (EVA) Study. Arterioscler Thromb Vasc Biol. 2000;20:1622.
30. Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA, Davis A, Crow MK, Sammaritano L, Levine DM, Shankar BA, Moeller E, Salmon JE. Arterial stiffness in chronic inflammatory diseases. Hypertension. 2005;46: 194-199.
31. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008; 59:1690-1697.
32. Goodson N, Marks J, Lunt M, Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis. 2005;64:1595-1601.
33. Pasceri V, Yeh ETH. A Tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation. 1999;100:2124-2126.
34. Aubry MC, Maradit-Kremers H, Reinalda MS, Crowson CS, Edwards WD, Gabriel SE. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol. 2007;34:937-942.
35. Douglas KM, Pace AV, Treharne GJ, Saratzis A, Nightingale P, Erb N, Banks MJ, Kitas GD. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis. 2006; 65:348-353.
36. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25: 932-943.
37. Furumoto T, Fujii S, Saito N, Mikami T, Kitabatake A. Relationships between brachial artery flow mediated dilation and carotid artery intima-media thickness in patients with suspected coronary artery disease. Jpn Heart J. 2002;43:117-125.
38. John H, Kitas G, Toms T, Goodson N. Cardiovascular co-morbidity in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2009;23: 71-82.
39. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173-1177.
40. Jacobsson LTH, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005;32:1213-1218.